About this trial
The goal of this clinical trial is to learn if tranexamic acid (TXA) helps reduce bleeding during bariatric surgery, such as laparoscopic sleeve gastrectomy (LSG) and mini gastric bypass (MGB). It will also look at how safe TXA is for people undergoing these procedures. The main questions it aims to answer are:
Does TXA reduce the amount of blood loss during bariatric surgery? Are there any side effects or complications in patients who receive TXA? Researchers will compare TXA to standard care (no TXA) to see if it is effective in reducing bleeding.
Participants will:
Receive either TXA or no TXA (placebo) before surgery Undergo standard bariatric surgery (LSG or MGB) Have their blood loss, hemoglobin levels, and any complications monitored during and after surgery
Eligibility criteria
Qualifiers
Patients above 18 years of age AND
Undergoing Laparoscopic Sleeve Gastrectomy and MGB
Morbid obesity
Disqualifiers
Patients on anti-platelets/anti-coagulants
Patients with inherited or acquired bleeding disorders
Patients with any acute medical condition predisposing to bleeding
Hormonal contraceptives
Trial design
Treatments tested in this trial
- Tranexamic Acid
- Normal Saline (Placebo)